French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome

French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome

This is a non-interventional registry of children treated with Norditropin® for short stature due to Noonan Syndrome (NS). This study aims to provide data on long-term growth evolution and safety of Norditropin® as well as Health Related Quality of Life (HRQoL) data. This registry will include the entirety of children treated with Norditropin® for short stature due to NS over the inclusion period. The decision to initiate treatment with commercially available Norditropin® is made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

Inclusion Criteria:

• Patients with a clinical and/or genetic diagnosis of NS
• Patients who are treated with Norditropin® (already treated or initiating) and who are followed in a participating center
• The decision to initiate treatment with commercially available Norditropin® has been made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study

Exclusion Criteria:

• Patients/Parents/LAR opposed to the collection and processing of their children's medical data
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation